Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INVITAE CORPORATION

(NVTA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
30.04(c) 29.77(c) 29.63(c) 29.74(c) 30.83 Last
3 491 925 2 356 377 3 369 424 2 272 846 1 462 720 Volume
-3.63% -0.90% -0.47% +0.37% +3.67% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 484 M - -
Net income 2021 -530 M - -
Net Debt 2021 342 M - -
P/E ratio 2021 -11,7x
Yield 2021 -
Sales 2022 673 M - -
Net income 2022 -653 M - -
Net Debt 2022 378 M - -
P/E ratio 2022 -9,77x
Yield 2022 -
Capitalization 6 464 M 6 464 M -
EV / Sales 2021 14,1x
EV / Sales 2022 10,2x
Nbr of Employees 2 600
Free-Float 97,0%
More Financials
Company
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for... 
More about the company
Ratings of Invitae Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about INVITAE CORPORATION
09/09VC DAILY : Digital Health Is Booming, but VC Doesn't See a Bubble Forming
DJ
09/07INVITAE : Ciitizen Announcement Conference Call Presentation
PU
09/07INVITAE : — Combination to bring together the power of genomic and clinical..
PU
09/07INVITAE CORP : Unregistered Sale of Equity Securities, Regulation FD Disclosure,..
AQ
09/07INVITAE : to Acquire Consumer Health Tech Company Ciitizen in $325 Million Deal
MT
09/07INVITAE : to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Pl..
PR
09/07Invitae Corporation entered into definitive agreement to acquire Ciitizen Cor..
CI
09/01INVITAE : to Present at the Morgan Stanley 19th Annual Global Healthcare Confere..
PR
08/19INVITAE : Significant Insider Sales in Shares of Invitae (NVTA) Extends the Sell..
MT
08/18INSIDER TRENDS : 90-Day Insider Selling Trend Extended at Invitae
MT
08/18INSIDER TRENDS : Invitae Insider Extends 90-Day Selling Trend
MT
08/18INSIDER TRENDS : Invitae Insider Sale Scaling Back 90-Day Buy Trend
MT
08/09INVITAE : Management's Discussion and Analysis of Financial Condition and Result..
AQ
08/09INVITAE : to Present at the UBS Genomics 2.0 and MedTech Innovations Summit
PR
08/09Global markets live: Alibaba, Citigroup, Tyson Foods, Veoneer, Cisco...
More news
News in other languages on INVITAE CORPORATION
08/19Une importante vente d'initiés sur les actions d'Invitae (NVTA) prolonge la t..
08/09EN DIRECTO DESDE LOS MERCADOS : Sika, ByteDance, Renault, Logitech, PostNL, Aram..
08/09MADRID STOCK EXCHANGE : Resultados casi perfectos
08/09STOCK MARKET PARIS : Des résultats presque parfaits
08/09EN DIRECT DES MARCHES : EDF, Renault, Atos, Rémy Cointreau, Logitech, PostNL, Ar..
More news
Analyst Recommendations on INVITAE CORPORATION
More recommendations
Chart INVITAE CORPORATION
Duration : Period :
Invitae Corporation Technical Analysis Chart | NVTA | US46185L1035 | MarketScreener
Technical analysis trends INVITAE CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 29,74 $
Average target price 40,44 $
Spread / Average Target 36,0%
EPS Revisions
Managers and Directors
Sean Emerson George Chairman, President & Chief Executive Officer
Roxi Wen Chief Financial Officer
Robert Nussbaum Chief Medical Officer
Eric Olivares Chief Science Officer
Layton Wedgeworth Chief Technology Officer
Sector and Competitors